Clinical Trials Browser

Phase 2 × Multiple Myeloma × Azacitidine × Clear all

NCT04407442 2024-04-30

Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab

Phase 2 Terminated

5 enrolled 12 charts

Plasma cell

Multiple Myeloma

NCT00006019 2013-06-24

Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate Cancer

Phase 2 Completed

GenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Leukemia, Leukemia, Monocytic, Acute, Lung Neoplasms, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Prostatic Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Leukemia, Promyelocytic, Acute, Leukemia, Myelomonocytic, Acute, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Neoplasms, Plasma Cell